Nintedanib Ester is a pivotal pharmaceutical API and analytical reference standard in the treatment of idiopathic pulmonary fibrosis and certain cancers, functioning as a potent triple angiokinase inhibitor that targets VEGFR, FGFR, and PDGFR simultaneously . As a small molecule kinase inhibitor, Nintedanib Ester binds to the ATP-binding site in the kinase domain and blocks the signaling pathways that drive angiogenesis, fibrosis, and tumor progression . Nintedanib Ester inhibits VEGFR-1/2/3 with IC₅₀ values of 34, 21, and 13 nM respectively, FGFR-1/2/3 with IC₅₀ values of 69, 37, and 108 nM, and PDGFRα/β with IC₅₀ values of 59 and 65 nM . Nintedanib Ester is supplied with detailed characterization data and serves as both the API for commercial production and a reference standard for analytical method development and quality control applications. Nintedanib Ester has a molecular weight of 539.6 g/mol and appears as a yellow to yellow-green solid .
|
Parameter |
Specification |
|
Product Name |
Nintedanib Ester |
|
CAS Number |
|
|
Molecular Formula |
|
|
Molecular Weight |
When your IPF or oncology API manufacturing campaign or ANDA filing requires reliable Nintedanib Ester, Cosperpharm delivers with the analytical rigor, documentation depth, and supply flexibility that pharmaceutical customers demand.
Consistent quality starts with the oxindole scaffold. Nintedanib Ester's complex molecular architecture—featuring an oxindole core with a methyl ester and a substituted phenylamino group—demands rigorous quality control throughout synthesis . Any impurity in this starting material will compromise your final API's kinase inhibition profile and therapeutic efficacy. Our analytical release protocol for Nintedanib Ester includes HPLC purity verification (≥98%), identity confirmation by NMR and MS, residual solvent analysis, and water content determination—because your final API's pharmacological profile depends on the quality of this oxindole-based scaffold .
Documentation that supports regulatory submission. As an API and reference standard, every Cosperpharm shipment of Nintedanib Ester includes a Certificate of Analysis (COA) with batch-specific HPLC purity, chromatographic traceability, and residual solvent data—structured for direct insertion into your method validation package. DMF-ready documentation, stability summaries, and custom quality agreements are available upon request.
Flexible supply across all development stages. Cosperpharm supplies Nintedanib Ester across the full range of applications—from milligram reference standard quantities for QC impurity profiling and analytical method development, to gram-scale batches for process validation and pilot production, to bulk quantities for commercial manufacturing. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.
Technical support for the full synthetic cascade. Our process chemistry team can advise on synthetic route optimization—including the Pd-catalyzed Heck/Buchwald–Hartwig cascade approach, impurity profiling, and analytical methods for detecting process-related impurities . We have extensive experience with this oxindole scaffold across multiple manufacturing campaigns.
Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and analytical laboratories worldwide, with full customs documentation included. Volume discounts apply at larger scales, and we communicate lead times upfront—no hidden fees, no unexpected delays.
Potent Triple Angiokinase Inhibitor
Nintedanib Ester is a potent, ATP-competitive inhibitor of VEGFR-1/2/3 (IC₅₀ = 34/21/13 nM), FGFR-1/2/3 (IC₅₀ = 69/37/108 nM), and PDGFRα/β (IC₅₀ = 59/65 nM) . This simultaneous inhibition of three key growth factor receptors makes Nintedanib Ester a uniquely effective therapy for both fibrotic and neoplastic diseases.
Orally Bioavailable with Established Clinical Utility
Nintedanib Ester is an orally administered therapeutic approved for idiopathic pulmonary fibrosis and certain cancers, with demonstrated antiangiogenic and antifibrotic efficacy in vivo . The bioavailability of Nintedanib Ester is 4.7% with a half-life of 10–15 hours .
Unique Oxindole Scaffold
The oxindole core with a methyl ester at the 6-position provides Nintedanib Ester with a unique molecular architecture optimized for ATP-binding site occupancy in multiple kinase domains . This structural design enables the distinct triple-kinase inhibition profile that differentiates Nintedanib Ester from other kinase inhibitors.
Dual-Use: API and Analytical Reference Standard
Nintedanib Ester serves as both the active pharmaceutical ingredient for commercial Ofev® and Vargatef® production and as a reference standard for analytical method development, method validation, and quality control applications.
Q1: What is Nintedanib Ester used for?
A: Nintedanib Ester is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and is also used in certain cancers including non-small-cell lung cancer, ovarian cancer, and colorectal cancer . It functions as a triple angiokinase inhibitor targeting VEGFR, FGFR, and PDGFR.
Q2: What is the mechanism of action of Nintedanib Ester?
A: Nintedanib Ester is a potent ATP-competitive inhibitor of VEGFR-1/2/3, FGFR-1/2/3, and PDGFRα/β . It binds to the ATP-binding site in the kinase domain and blocks signaling pathways that drive angiogenesis and fibrosis .
Interested in Nintedanib Ester for your IPF or oncology API program, impurity reference standard needs, or kinase inhibitor research? Cosperpharm is ready to support your project. Contact our team today for a quote, technical documentation, or to discuss your specific requirements—we're here to help you succeed.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
